Expert Reviews in Molecular Medicine,
Journal Year:
2022,
Volume and Issue:
24
Published: Jan. 1, 2022
Abstract
Prostate
cancer
(PC)
presents
great
challenges
in
early
diagnosis
and
often
leads
to
unnecessary
invasive
procedures
as
well
over
treatment,
thus
highlighting
the
need
for
promising
diagnostic
biomarkers.
The
aim
of
this
review
is
provide
an
up-to-date
summary
chronologically
existing
metabolomics
PC
biomarkers,
their
potential
improve
clinical
reduce
proliferation
monitoring
PC.
systematic
research
was
conducted
on
PubMed
accordance
with
PRISMA
guidelines
report
majority
studies
distinguished
malignant
from
benign
prostate
few
explored
biomarkers
associated
progression
present
summarises
primary
outcomes
most
significant
extend
our
knowledge
We
observed
divergent
inter-laboratory
technical
employing
different
statistical
approaches
produced
abundant
information
regarding
metabolites
perturbation.
Since
still
its
phase,
it
vital
that
we
dig
out
specific,
sensitive
accurate
metabolic
signatures
conduct
more
milestone
findings
comparable
sample
sizes
validate
corroborate
findings.
Journal of Advanced Research,
Journal Year:
2023,
Volume and Issue:
54, P. 195 - 210
Published: Jan. 18, 2023
IQGAP3
possesses
oncogenic
actions;
its
impact
on
prostate
cancer
(PC)
remains
unclear.We
will
investigate
IQGAP3's
association
with
PC
progression,
key
mechanisms,
prognosis,
and
immune
evasion.IQGAP3
expression
in
was
examined
by
immunohistochemistry
using
multiple
datasets.
network
analyzed
for
pathway
alterations
used
to
construct
a
multigene
signature
(SigIQGAP3NW).
SigIQGAP3NW
characterized
LNCaP
cell-derived
castration-resistant
PCs
(CRPCs),
prognostic
value
26
human
types,
studied
evasion.Increases
associated
tumorigenesis,
tumor
grade,
metastasis,
p53
mutation.
correlative
genes
were
dominantly
involved
mitosis.
correlated
PLK1
TOP2A
at
Spearman
correlation/R
=
0.89
(p
≤
3.069e-169).
Both
correlations
enriched
advanced
Taxane-treated
CRPCs
occurred
high
levels
(R
>
0.8)
types.
effectively
predicted
recurrence
poor
prognosis
independent
cohorts
across
stratified
after
adjustment
age
diagnosis,
stage,
surgical
margin.
component
upregulated
PC,
cell-produced
CRPC,
showed
an
cell
infiltration,
including
Treg
other
cancers.
RELT,
gene,
elevations
of
checkpoints
the
infiltration
myeloid-derived
suppressor
cells
RELT
predict
response
checkpoint
blockade
(ICB)
therapy.In
cancers,
robustly
correlates
expression,
and/or
mortality
risk
resistance
ICB
therapy.
inhibitors
should
be
investigated
treating
cancers
elevated
expression.
can
developed
clinical
applications
stratification
management
Research in Pharmaceutical Sciences,
Journal Year:
2023,
Volume and Issue:
18(4), P. 439 - 448
Published: June 1, 2023
Prostate
cancer
is
the
second
cause
of
death
among
men.
Nowadays,
treating
various
cancers
with
medicinal
plants
more
common
than
other
therapeutic
agents
due
to
their
minor
side
effects.
This
study
aimed
evaluate
effect
taraxasterol
on
prostate
cell
line.The
line
(PC3)
was
cultured
in
a
nutrient
medium.
MTT
method
and
trypan
blue
staining
were
used
viability
cells
presence
different
concentrations
taraxasterol,
IC50
calculated.
Real-time
PCR
measure
expression
MMP-9,
MMP-2,
uPA,
uPAR,
TIMP-2,
TIMP-1
genes.
Gelatin
zymography
determine
MMP-9
MMP-2
enzyme
activity
levels.
Finally,
invasion,
migration,
adhesion
investigated.Taraxasterol
decreased
survival
rate
PC3
at
time-dependently
(24,
48,
72
h).
Taraxasterol
reduced
percentage
adhesion,
migration
by
74,
56,
76
percent,
respectively.
results
revealed
that
gene
expressions
taraxasterol-treated
groups,
but
TIMP-2
increased
significantly.
Also,
significant
decrease
level
enzymes
observed
treated
taraxasterol.The
present
confirmed
role
preventing
metastasis
in-vitro
study.
Cancer Reports,
Journal Year:
2024,
Volume and Issue:
7(8)
Published: Aug. 1, 2024
ABSTRACT
Background
Cancer
is
a
critical
public
health
issue
that
imposes
considerable
economic
burden,
especially
in
low‐resource
countries.
In
Bangladesh,
there
has
been
noticeable
lack
of
research
focusing
on
the
burden
associated
with
cancer.
Aims:
This
study
aimed
to
examine
cancer
care
and
contributing
factors.
Methods
cross‐sectional
included
623
patients.
Data
were
collected
between
January
May
2022.
The
magnitude
(no
extreme
burden)
was
outcome
variable.
A
logistic
regression
model
performed
determine
factors
Results
Overall,
34%
survivors
experienced
due
treatment
costs.
Patients
prostate
(relative
risk
ratio,
RRR
=
23.24;
95%
confidence
interval,
CI:
1.97,
273.70),
bone
(RRR
5.85;
1.10,
31.04),
liver
4.94;
1.29,
18.9)
reported
significantly
higher
compared
patients
other
cancers.
for
diagnosed
Stage
III
38.69;
6.17,
242.72)
IV
24.74;
3.22,
190.11)
0.
from
low‐income
households
suffered
nine
times
more
8.85;
4.05,
19.36)
those
high‐income
households.
Conclusion
Our
found
disproportionately
high
among
cancer,
across
disease
sites,
stages,
income
quintiles.
prostate,
bone,
advanced
stage.
findings
underscore
importance
early
detection
before
metastasis
which
may
lead
efficient
treatment,
avoid
progression,
lower
management
costs,
better
outcomes.
experience
an
highlighting
need
affordable
healthcare
services,
financial
support,
subsidies.
JNCI Cancer Spectrum,
Journal Year:
2024,
Volume and Issue:
8(5)
Published: Aug. 24, 2024
Abstract
Background
Adiposity
has
been
characterized
as
a
modifiable
risk
factor
for
prostate
cancer.
Its
association
with
outcomes
after
cancer
diagnosis,
however,
must
be
better
understood,
and
more
evidence
is
needed
to
facilitate
the
development
of
lifestyle
guidance
patients
Methods
We
investigated
associations
between
adiposity
indices
close
diagnosis
(up
2
years
before
or
up
5
diagnosis)
mortality
in
1968
men
European
Prospective
Investigation
into
Cancer
Nutrition
cohort.
Men
were
followed
median
9.5
years.
Cox
proportional
hazards
models
adjusted
age
year
disease
stage
grade,
smoking
history
stratified
by
country.
Results
Each
5-unit
increment
prediagnosis
postdiagnosis
body
mass
index
combined
was
associated
30%
higher
rate
all-cause
49%
cancer–specific
mortality.
Similarly,
each
35%
51%
The
less
strong
index,
lower
number
analyses.
Less
clear
positive
shown
waist
circumference,
hip
ratio,
but
data
limited.
Conclusions
Elevated
levels
could
lead
mortality;
therefore,
are
encouraged
maintain
healthy
weight.
Additional
research
confirm
whether
excessive
worsen
prognosis.
Expert Reviews in Molecular Medicine,
Journal Year:
2022,
Volume and Issue:
24
Published: Jan. 1, 2022
Abstract
Prostate
cancer
(PC)
presents
great
challenges
in
early
diagnosis
and
often
leads
to
unnecessary
invasive
procedures
as
well
over
treatment,
thus
highlighting
the
need
for
promising
diagnostic
biomarkers.
The
aim
of
this
review
is
provide
an
up-to-date
summary
chronologically
existing
metabolomics
PC
biomarkers,
their
potential
improve
clinical
reduce
proliferation
monitoring
PC.
systematic
research
was
conducted
on
PubMed
accordance
with
PRISMA
guidelines
report
majority
studies
distinguished
malignant
from
benign
prostate
few
explored
biomarkers
associated
progression
present
summarises
primary
outcomes
most
significant
extend
our
knowledge
We
observed
divergent
inter-laboratory
technical
employing
different
statistical
approaches
produced
abundant
information
regarding
metabolites
perturbation.
Since
still
its
phase,
it
vital
that
we
dig
out
specific,
sensitive
accurate
metabolic
signatures
conduct
more
milestone
findings
comparable
sample
sizes
validate
corroborate
findings.
